iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $102.43, for a total transaction of $256,075.00. Following the sale, the chief executive officer directly owned 2,240,000 shares in the company, valued at approximately $229,443,200. This trade represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

iRadimed Price Performance

Shares of iRadimed stock traded down $1.34 during trading hours on Wednesday, reaching $101.46. The company had a trading volume of 41,499 shares, compared to its average volume of 72,331. The firm has a market cap of $1.30 billion, a PE ratio of 57.68 and a beta of 1.12. iRadimed Corporation has a one year low of $47.48 and a one year high of $107.90. The business has a fifty day simple moving average of $100.44 and a 200 day simple moving average of $89.15.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. The business had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, research analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Monday, February 23rd. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s dividend payout ratio is presently 45.71%.

Institutional Investors Weigh In On iRadimed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRMD. CWM LLC lifted its position in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 211 shares during the period. Quarry LP purchased a new stake in shares of iRadimed in the 3rd quarter worth about $40,000. Farther Finance Advisors LLC increased its stake in shares of iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 397 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in iRadimed during the 3rd quarter valued at about $47,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on IRMD. Roth Mkm restated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Lake Street Capital restated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.